Side effects of traditional analgo-sedative agents call the attention to alternative strategies of sedation for critically ill patients; volatile anaesthetics (VAs) are considered potential substitutes in selected categories of patients. MIRUSTM (Pall Corporation and TIM Germany) is an innovative system for the administration of VAs to these patients admitted in intensive care unit (ICU). The aim of this study was to analyse the clinical and economical characteris- tics of MIRUSTM, following the Health Technology Assessment principles (HTA); in particular, the study was focused on defining a cost/efficacy ratio of the use of MIRUSTM in an ICU with 8 beds and 80 procedures/year. HTA allows predicting the system impact in the clinical pathway before material introduction. The assessment showed that MIRUSTM could be innovative, safe and efficient, especially when applied to critically ill patients with compromised organ func- tion. For the purposes of assessment, three classes of ICU treatments have been defined: short- (6-24 hours), medium- (24-96 hours) and long-term (>96 hours) sedation (SS, MS, LS). Based on the technical characteristics of system, MIRUSTM could be considered unfit for LS. Considering clinical characteristics, effects on patients, sedation times and costs, the HTA shows how the procedure costs are different for each class. In conclusion, the use of MIRUSTM could be useful and effective for critically ill patients, in which standard sedation may be associated with drug hangover. This assessment seems economically advantageous for SS, where cost/efficacy ratios are positive performing 400 procedures/year, while for MS the cost of drugs impacts on the procedure cost. Therefore, looking at the potential clinical benefits on all potential treatable patients, the best addition strategy of the system in the hospital should be evaluated to optimize the cost/efficacy ratio.

A Preliminary Cost/Efficacy Analysis of MIRUS System for Sedation of Critical Patients / Ciagli Elena, Frosini Francesco, Cocchi Duccio, Tortoli Piero, Romagnoli Stefano, Quarti Cinzia, De Gaudio Angelo Raffaele, Belardinelli Andrea. - ELETTRONICO. - (2019), pp. 95-99. (Intervento presentato al convegno World Congress on Medical Physics and Biomedical Engineering 2018 tenutosi a Praga nel 2018) [10.1007/978-981-10-9038-7_17].

A Preliminary Cost/Efficacy Analysis of MIRUS System for Sedation of Critical Patients

CIAGLI, ELENA
Writing – Original Draft Preparation
;
Frosini Francesco
Writing – Review & Editing
;
Cocchi Duccio
Membro del Collaboration Group
;
Tortoli Piero
Supervision
;
Romagnoli Stefano;De Gaudio Angelo Raffaele;
2019

Abstract

Side effects of traditional analgo-sedative agents call the attention to alternative strategies of sedation for critically ill patients; volatile anaesthetics (VAs) are considered potential substitutes in selected categories of patients. MIRUSTM (Pall Corporation and TIM Germany) is an innovative system for the administration of VAs to these patients admitted in intensive care unit (ICU). The aim of this study was to analyse the clinical and economical characteris- tics of MIRUSTM, following the Health Technology Assessment principles (HTA); in particular, the study was focused on defining a cost/efficacy ratio of the use of MIRUSTM in an ICU with 8 beds and 80 procedures/year. HTA allows predicting the system impact in the clinical pathway before material introduction. The assessment showed that MIRUSTM could be innovative, safe and efficient, especially when applied to critically ill patients with compromised organ func- tion. For the purposes of assessment, three classes of ICU treatments have been defined: short- (6-24 hours), medium- (24-96 hours) and long-term (>96 hours) sedation (SS, MS, LS). Based on the technical characteristics of system, MIRUSTM could be considered unfit for LS. Considering clinical characteristics, effects on patients, sedation times and costs, the HTA shows how the procedure costs are different for each class. In conclusion, the use of MIRUSTM could be useful and effective for critically ill patients, in which standard sedation may be associated with drug hangover. This assessment seems economically advantageous for SS, where cost/efficacy ratios are positive performing 400 procedures/year, while for MS the cost of drugs impacts on the procedure cost. Therefore, looking at the potential clinical benefits on all potential treatable patients, the best addition strategy of the system in the hospital should be evaluated to optimize the cost/efficacy ratio.
2019
IFMBE Proceedings
World Congress on Medical Physics and Biomedical Engineering 2018
Praga
2018
Ciagli Elena, Frosini Francesco, Cocchi Duccio, Tortoli Piero, Romagnoli Stefano, Quarti Cinzia, De Gaudio Angelo Raffaele, Belardinelli Andrea...espandi
File in questo prodotto:
File Dimensione Formato  
10.1007-978-981-10-9038-7_17.pdf

Accesso chiuso

Tipologia: Pdf editoriale (Version of record)
Licenza: Tutti i diritti riservati
Dimensione 364.64 kB
Formato Adobe PDF
364.64 kB Adobe PDF   Richiedi una copia

I documenti in FLORE sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificatore per citare o creare un link a questa risorsa: https://hdl.handle.net/2158/1129514
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 0
  • ???jsp.display-item.citation.isi??? 0
social impact